MENU
+Compare
MYGN
Stock ticker: NASDAQ
AS OF
Jul 10 closing price
Price
$5.50
Change
-$0.22 (-3.85%)
Capitalization
1.93B

MYGN Myriad Genetics Forecast, Technical & Fundamental Analysis

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease... Show more

Industry: #Biotechnology
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for MYGN with price predictions
Jul 10, 2025

Aroon Indicator for MYGN shows an upward move is likely

MYGN's Aroon Indicator triggered a bullish signal on July 10, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator showed a similar pattern. In of the 196 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 26, 2025. You may want to consider a long position or call options on MYGN as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

MYGN moved above its 50-day moving average on July 01, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MYGN crossed bullishly above the 50-day moving average on July 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MYGN broke above its upper Bollinger Band on July 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MYGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.460) is normal, around the industry mean (24.348). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.357) is also within normal values, averaging (42.660).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

MYGN is expected to report earnings to fall 72.33% to 0 cents per share on July 31

Myriad Genetics MYGN Stock Earnings Reports
Q2'25
Est.
$-0.01
Q1'25
Beat
by $0.03
Q4'24
Est.
$0.03
Q3'24
Beat
by $0.04
Q2'24
Beat
by $0.06
The last earnings report on May 06 showed earnings per share of -2 cents, beating the estimate of -5 cents. With 1.38M shares outstanding, the current market capitalization sits at 1.93B.
A.I. Advisor
published General Information

General Information

a developer of therapeutic and predictive medicine products

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
320 Wakara Way
Phone
+1 801 584-3600
Employees
2700
Web
https://www.myriad.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GQEFX34.60N/A
N/A
GMO Quality IV
WEEIX11.28N/A
N/A
TETON Westwood Equity I
MNDIX32.35N/A
N/A
MFS New Discovery I
TAVFX66.46N/A
N/A
Third Avenue Value Instl
TLORX9.64N/A
N/A
Transamerica Large Value Opps R

MYGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-3.85%
WAT - MYGN
39%
Loosely correlated
+1.17%
ATEC - MYGN
34%
Loosely correlated
+0.78%
VCYT - MYGN
31%
Poorly correlated
+3.54%
AORT - MYGN
31%
Poorly correlated
+1.28%
GH - MYGN
30%
Poorly correlated
+0.49%
More